Top News

Isis Pharmaceuticals Earns $2M From GlaxoSmithKline




Carlsbad-based biopharmaceuticals developer Isis Pharmaceuticals said this morning that it has earned $2M from GlaxoSmithKline, related to advancement of a compound in Phase 2/3 studies. The company said the milestone payment from GSK was related to its ISIS-TTRRx studies aimed at patients with familial amyloid polyneuropathy (FAP). Isis said the $2M is part of $50M in potential milestone payments that Isis is eligible to earn from GlaxoSmithKline.


 

Marketplace


 

 

Latest Headlines

Browse Issues

 
 

Keep up with all of the latest Southern California high tech news via email (it's free!)



or Cancel